Virbac recently announced its first-half 2025 financial results, showing group revenue of €738.3 million for H1 2025. At constant exchange rates and scope, this represents a 5.6% increase compared to the same period in 2024, with companion animal business revenue growing 7.1%.

The group's second-quarter revenue reached €363.1 million, marking a 6.4% increase compared to Q2 2024. Second-quarter companion animal business growth exceeded 8%, particularly driven by pet food revenue growth, partially attributed to the acquisition of Mopsan. Additionally, Virbac launched new products for treating hyperadrenocorticism (Cushing's syndrome), along with strong performance from reproductive and osteoarthritis product lines, contributing to companion animal segment growth.

By region, Virbac's U.S. subsidiary achieved 9.2% revenue growth, driven by the launch of new products targeting animal muscle function, canine osteoarthritis product lines, and osteoarthritis treatments in the American market. Latin America recorded an 8.1% growth rate, with companion animal segment growing 6.8%, particularly strong growth observed in Mexico, Brazil, and Colombia.

The Far East region grew 2.8% at constant exchange rates and scope, benefiting from positive growth momentum across all countries in the region, except Vietnam, where activities declined 17.8% due to African swine fever outbreaks. The Pacific region experienced a 7.9% decline in first-half activities at constant exchange rates and scope. This decrease was primarily attributed to Australia's decline of 11.4%, partially offset by New Zealand's sales growth of 7.6%. Australia is expected to return to growth in the second half, benefiting from improved market conditions and normalized distributor inventory levels.

Looking ahead to 2025, at constant exchange rates and within a 4% to 6% range, Virbac projects annual revenue growth of 16% compared to the previous year.